Cargando…
The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease
One of the major consequences of the lack of a functional VHL protein in von Hippel-Lindau disease, a rare cancer, is the constitutive activation of the HIF pathway. This activation ends up in the generation of Central Nervous System (CNS) Hemangioblastomas among other tumours along the lifespan of...
Autores principales: | Cuesta, A. M., Albiñana, V., Gallardo-Vara, E., Recio-Poveda, L., de Rojas-P, I., de Las Heras, K. Villar Gómez, Aguirre, D. T., Botella, L. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624208/ https://www.ncbi.nlm.nih.gov/pubmed/31296894 http://dx.doi.org/10.1038/s41598-019-46448-6 |
Ejemplares similares
-
Effects of norepinephrine and β2 receptor antagonist ICI 118,551 on whisker hair follicle mechanoreceptors dissatisfy Merkel discs being adrenergic synapses
por: Sonekatsu, Mayumi, et al.
Publicado: (2019) -
Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: phase III clinical trial
por: González-Rodríguez, Beatriz, et al.
Publicado: (2019) -
Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients
por: Albiñana, Virginia, et al.
Publicado: (2015) -
Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel–Lindau Disease
por: Albiñana, Virginia, et al.
Publicado: (2020) -
Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease
por: Albiñana, Virginia, et al.
Publicado: (2017)